Source - RNS
RNS Number : 4836T
Integumen PLC
21 March 2019
 

AIM share code: SKIN

 

21 March 2019

 

Integumen PLC

("Integumen" or "Company")

 

Labskin take up additional space with joint development partners at University of Bradford

 

Integumen, the AIM-quoted company, announces the further expansion of its subsidiary, Labskin, which has agreed to occupy secure workspace in the Digital Health Enterprise Zone (SHEZ) at the University of Bradford, UK in early April 2019. This is an extension to our already enlarged laboratories in York, UK.

 

This workspace affords the Labskin team close proximity to our collaboration partners at the Centre for Skin Sciences (CSS) who are based in the DHEZ and. Labskin and CSS are engaging in preliminary research, before embarking on a larger joint development project, with the support of local and national technology funding partners.

 

Gerard Brandon - CEO of Integumen plc, comments:

 

The Integumen ethos behind our plans for growth in the 21st Century draws upon a 395-year-old phrase. "No man is an island" (John Donne). Our development partners continue to grow, and we look forward to reaping the benefit of this collaboration, which represents our first external development facility within the University of Bradford and the Centre of Skin Science." 

 

Contacts

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 643

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker

+44 (0) 20 3621 4120

 

About Integumen:

 

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

 

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRASESFLSFUSEID